首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
【24h】

WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.

机译:WIF-1启动子区域高甲基化作为非小细胞肺癌相关恶性胸腔积液的辅助诊断标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Malignant pleural effusion is an important staging criterion in non-small cell lung cancer (NSCLC). Although cytologic examination remains the major diagnostic tool for NSCLC-related malignant pleural effusion, sometimes other invasive methods maybe required. Aberrant activation of Wnt signaling pathway due to Wnt inhibitory factor-1 (WIF-1) promoter region hypermethylation is common in NSCLC, and can be specifically detected by methylation-specific polymerase chain reaction (MSP). We hypothesized that WIF-1 promoter region MSP can be used to improve the diagnostic yield of NSCLC-related malignant pleural effusion. METHODS: We performed WIF-1 promoter region MSP in 36 definite malignant pleural effusions from consecutive NSCLC patients and 35 pleural effusion specimens of benign origin. Pleural effusion cells were collected for DNA extraction. After bisulfite treatment, DNA was amplified by methylation-specific and unmethylation-specific primers, respectively, to identify the methylation status of WIF-1 promoter region. RESULTS: The results of WIF-1 promoter region MSP were positive in 25 (69.4%) of 36 NSCLC patients with malignant pleural effusion. In addition, the results of WIF-1 promoter region MSP were negative in all 35 patients with pleural effusion of benign origin. The age, gender, and smoking status of patients were not correlated with the methylation status of WIF-1 promoter region in NSCLC-related malignant pleural effusion. CONCLUSIONS: WIF-1 promoter region MSP might be used as an adjuvant tool to complement cytologic examination for the diagnosis of NSCLC-related malignant pleural effusion.
机译:目的:恶性胸腔积液是非小细胞肺癌(NSCLC)的重要分期标准。尽管细胞学检查仍然是NSCLC相关性恶性胸腔积液的主要诊断工具,但有时可能需要其他侵入性方法。由于Wnt抑制因子1(WIF-1)启动子区域超甲基化引起的Wnt信号通路异常激活在NSCLC中很常见,可以通过甲基化特异性聚合酶链反应(MSP)进行特异性检测。我们假设WIF-1启动子区域MSP可用于提高NSCLC相关性恶性胸腔积液的诊断率。方法:我们从连续的NSCLC患者的36例恶性胸腔积液和35例良性胸腔积液样本中进行了WIF-1启动子区MSP。收集胸腔积液用于DNA提取。亚硫酸氢盐处理后,分别通过甲基化特异性和非甲基化特异性引物扩增DNA,以鉴定WIF-1启动子区域的甲基化状态。结果:36例NSCLC恶性胸腔积液患者中,WIF-1启动子区MSP的结果为阳性(25例,占69.4%)。另外,在所有35例良性胸腔积液患者中,WIF-1启动子区MSP的结果均为阴性。在NSCLC相关的恶性胸腔积液中,患者的年龄,性别和吸烟状态与WIF-1启动子区域的甲基化状态无关。结论:WIF-1启动子区MSP可作为辅助细胞学检查辅助诊断NSCLC相关的恶性胸腔积液。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号